Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
In This Article:
-
Preclinical results of EL-32 demonstrated statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model.
-
Elevai believes that EL-32 has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1 receptor agonists, by preserving muscle mass while decreasing fat mass.
-
Elevai plans to conduct additional animal studies to advance EL-32 towards an Investigational New Drug (IND) application.
NEWPORT BEACH, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Elevai Biosciences Inc. (“Elevai Biosciences”), a subsidiary of Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), today released encouraging past preclinical data from 2022 for EL-32, a pioneering dual-action blocker targeting myostatin and activin-A. Preclinical results generated from our licensing partner in a 2022 study indicated that EL-32 may offer a breakthrough approach to obesity treatment by simultaneously preserving muscle mass and reducing fat mass when used alongside popular weight loss therapies such as GLP-1 receptor agonists.
EL-32, an engineered probiotic expressing dual myostatin & activin-A, focuses on two clinically validated targets that play an important role in regulating muscle. During 15-week preclinical studies on aged C57BL/6J mice, EL-32 administration resulted in statistically significant improvements across key measures of physical muscular function and body composition. Highlights from the results of these studies include:
-
Enhanced grip strength, with notable, statistically significant increases observed at week 15.
-
Improved motor performance, evidenced by longer, statistically significant rotarod latency durations.
-
Optimized body composition, demonstrated by DEXA scans.
“Popular GLP-1 medications like Ozempic and Mounjaro are faced with associated loss of muscle,” said Deniel Mero, Co-founder of Elevai Biosciences. Mero stated, “Myostatin and activin-A are two validated targets that have demonstrated potential in muscle mass, strength building, and are also being tested in clinical trials with GLP-1 medications. These validated pathways, literature and the preclinical data generated to date, gives us reasons to believe that EL-32 has the potential to treat obesity while preserving muscle.”
Based on the preclinical data from our licensing partner, Elevai believes that EL-32 has the potential to treat obesity in combination with GLP-1 by preserving muscle mass while decreasing fat mass. The Company intends to conduct additional animal studies to advance EL-32 towards an Investigational New Drug (IND) application. Full preclinical data is expected to be shared at a future scientific conference.